-
公开(公告)号：US08182805B2
公开(公告)日：2012-05-22
申请号：US12523328
申请日：2008-01-31
申请人： Hanna Viskari , Mikael Knip , Tapio Seiskari , Heikki Hyöty , Laura Kummola , Anita Kondrashova
发明人： Hanna Viskari , Mikael Knip , Tapio Seiskari , Heikki Hyöty , Laura Kummola , Anita Kondrashova
CPC分类号： A61K39/35 , A61K35/76 , C12N2770/32311 , C12N2770/32332
摘要： The present invention relates to prevention and treatment of allergic sensitization and diseases associated therewith by treatment with an enterovirus vaccine, wherein the enterovirus does not contain an exogenous nucleic acid sequence that is integrated into the viral genome and that encodes an allergen that induces said allergic sensitization.
摘要翻译： 本发明涉及通过肠道病毒疫苗的治疗来预防和治疗过敏性致敏及其相关疾病，其中肠道病毒不含有整合到病毒基因组中并编码诱导所述过敏致敏的变应原的外源性核酸序列 。
-
公开(公告)号：US20210023196A1
公开(公告)日：2021-01-28
申请号：US16995439
申请日：2020-08-17
申请人： Vactech Oy
发明人： Hyöty Heikki , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
IPC分类号： A61K39/125 , A61K39/12 , C07K16/10 , A61K39/13 , A61K39/39
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
3.发明申请Enterovirus Vaccines for Preventing or Treating Type 1 Diabetes (III) 审中-公开用于预防或治疗1型糖尿病的肠道病毒疫苗（III）公开(公告)号：US20120003240A1
公开(公告)日：2012-01-05
申请号：US13173542
申请日：2011-06-30
申请人： Heikki Hyoty , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valerie Lecouturier , Jeffrey Almond , Malin Flodstrom-Tullberg
发明人： Heikki Hyoty , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valerie Lecouturier , Jeffrey Almond , Malin Flodstrom-Tullberg
IPC分类号： A61K39/125 , A61K39/295 , A61P3/10 , A61K39/42 , A61P31/14
CPC分类号： A61K39/125 , A61K39/00 , A61K39/12 , A61K2039/505 , C07K14/005 , C12N2770/32322 , C12N2770/32334
摘要： Coxsackie B virus CBV1 has been found to be strongly associated with the risk of contracting type 1 diabetes. A vaccine comprising CBV1, a component thereof or an antibody thereto is provided for use in preventing or treating type 1 diabetes. In addition CBV2 was also found to be diabetogenic.
摘要翻译： 柯萨奇B病毒CBV1已被发现与1型糖尿病合并风险密切相关。 提供包含CBV1，其组分或其抗体的疫苗用于预防或治疗1型糖尿病。 此外，CBV2也被发现是致糖尿病。
-
4.发明申请公开(公告)号：US20120003238A1
公开(公告)日：2012-01-05
申请号：US13173386
申请日：2011-06-30
申请人： Heikki Hyoty , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valerie Lecouturier , Jeffrey Almond
发明人： Heikki Hyoty , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valerie Lecouturier , Jeffrey Almond
IPC分类号： A61K39/125 , A61P3/10 , A61K39/42
CPC分类号： A61K39/125 , A61K39/00 , A61K39/12 , A61K2039/5254 , C07K14/005 , C12N2770/32322 , C12N2770/32334
摘要： Some coxsackie B viruses have been found to have a protective effect on type 1 diabetes, while others increase the risk of the disease. This opens up new therapeutic implications in the form of vaccines. The protective viruses CBV3, CBV4, CBV5 and CBV6 may be used in live attenuated vaccines for preventing or treating type 1 diabetes. They may also be used for inducing an immune response against risk viruses like CBV1, and for eliminating the diabetogenic effect of the risk viruses. Type 1 diabetes may be prevented especially by vaccinating with live attenuated protective viruses CBV3, CBV4, CVB5 and CBV6, and further with inactivated diabetogenic/risk virus CBV1, components thereof or antibodies thereto.
摘要翻译： 已经发现一些柯萨奇B病毒对1型糖尿病具有保护作用，而另一些增加了该疾病的风险。 这为疫苗的形式开辟了新的治疗意义。 保护性病毒CBV3，CBV4，CBV5和CBV6可用于减毒疫苗，用于预防或治疗1型糖尿病。 它们还可用于诱导针对诸如CBV1之类的风险病毒的免疫应答，并且用于消除风险病毒的致糖尿病作用。 可以特别通过用活减毒的保护性病毒CBV3，CBV4，CVB5和CBV6接种疫苗，进一步与灭活的致糖尿病性/风险病毒CBV1，其组分或其抗体来预防1型糖尿病。
-
公开(公告)号：US11633468B2
公开(公告)日：2023-04-25
申请号：US16995439
申请日：2020-08-17
申请人： Vactech Oy
发明人： Hyöty Heikki , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
公开(公告)号：US20210220465A1
公开(公告)日：2021-07-22
申请号：US17224430
申请日：2021-04-07
申请人： Vactech Oy
发明人： Heikki Hyöty , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
IPC分类号： A61K39/125 , A61K39/12 , C07K16/10 , A61K39/13 , A61K39/39
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
公开(公告)号：US10780157B2
公开(公告)日：2020-09-22
申请号：US16265681
申请日：2019-02-01
申请人： Vactech Oy
发明人： Hyöty Heikki , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
公开(公告)号：US10258685B2
公开(公告)日：2019-04-16
申请号：US15465854
申请日：2017-03-22
申请人： Vactech Oy
发明人： Hyöty Heikki , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
9.发明申请公开(公告)号：US20120003239A1
公开(公告)日：2012-01-05
申请号：US13173470
申请日：2011-06-30
申请人： Heikki Hyoty , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valerie Lecouturier , Jeffrey Almond
发明人： Heikki Hyoty , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valerie Lecouturier , Jeffrey Almond
IPC分类号： A61K39/125 , A61P31/14 , A61P3/10 , A61K39/42 , C12Q1/70
CPC分类号： A61K39/125 , A61K39/00 , A61K39/12 , A61K2039/505 , C07K14/005 , C12N2770/32322 , C12N2770/32334 , G01N33/6893 , G01N2333/085 , G01N2800/044
摘要： New enteroviruses associated with type 1 diabetes have been found, which opens up new therapeutic and diagnostic implications. A vaccine against at least one enterovirus selected from coxsackie A virus CAV4, CAV5, CAVE and echovirus 18 is provided for use in preventing or treating type 1 diabetes. A diagnostic assay for predicting the risk of contracting type 1 diabetes based on the determination of said enteroviruses is also provided.
摘要翻译： 已经发现与1型糖尿病相关的新肠道病毒，这开启了新的治疗和诊断意义。 针对选自柯萨奇A病毒CAV4，CAV5，CAVE和回声病毒18的至少一种肠病毒的疫苗被提供用于预防或治疗1型糖尿病。 还提供了用于基于所述肠道病毒的确定来预测1型糖尿病合并风险的诊断测定法。
-
公开(公告)号：US11911456B2
公开(公告)日：2024-02-27
申请号：US17224430
申请日：2021-04-07
申请人： Vactech Oy
发明人： Heikki Hyöty , Mikael Knip , Olli Laitinen , Outi Tolonen , Minna Pulkki , Sami Oikarinen , Hanna-Riikka Honkanen , Valérie Lecouturier , Jeffrey Almond , Malin Flodström-Tullberg
CPC分类号： A61K39/125 , A61K39/12 , A61K39/13 , A61K39/39 , C07K16/1009 , A61K2039/505 , A61K2039/5252 , A61K2039/5258 , A61K2039/53 , A61K2039/55 , A61K2039/58 , C12N2770/32334
摘要： The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.016 秒)
